NeuroPace Inc: directors' dealings · United States · SEC (Form 4)

About NeuroPace Inc

NeuroPace Inc. (ticker: NPCE) is a U.S.-based medical device company listed on the Nasdaq stock market in the United States. Headquartered in Mountain View, California, the company focuses on epilepsy care, specifically the treatment of drug-resistant seizures through personalized brain neuromodulation. Its core business is centered on the RNS® System (Responsive Neurostimulation System), which NeuroPace describes as the first and only commercially available brain-responsive platform capable of delivering real-time therapy at the seizure source. For French, Belgian and Swiss investors, NeuroPace is therefore best viewed as a specialized medtech name with a differentiated clinical proposition in a focused but high-value therapeutic niche. ([neuropace.com](https://www.neuropace.com/about-neuropace/?utm_source=openai)) From a history standpoint, NeuroPace was founded in 1997, according to company filings. The business later reached a major milestone with its Nasdaq IPO in April 2021 under the symbol NPCE, marking the transition from a development-stage company to a commercial-stage platform with an established revenue base. Its headquarters remain in Mountain View, California, placing it within the Silicon Valley innovation ecosystem. ([investors.neuropace.com](https://investors.neuropace.com/static-files/420792b5-64c9-471a-be3c-de87f16f5f88?utm_source=openai)) Operationally, NeuroPace derives most of its revenue from the RNS System, an implantable device that monitors brain activity and delivers targeted electrical stimulation to reduce seizures in selected adult patients with focal epilepsy. The company has also highlighted product enhancements designed to streamline care, as well as data and AI-related initiatives aimed at improving epilepsy management. In 2025, NeuroPace announced a refocusing of its product portfolio, which suggests a sharper concentration on its core epilepsy franchise and the most strategically relevant growth opportunities. ([neuropace.com](https://www.neuropace.com/about-neuropace/?utm_source=openai)) In competitive terms, NeuroPace occupies a highly specialized position rather than competing as a broad-based medtech giant. Its key advantage lies in the combination of implantable technology, continuous brain data capture and personalized therapy, a proposition that is difficult for competitors to replicate quickly. At the same time, the company operates in a demanding market where clinical evidence, physician adoption and reimbursement are critical. Recent disclosures show positive commercial momentum: in the first quarter of 2026, revenue increased, driven by higher RNS System sales, and management raised full-year 2026 revenue guidance. NeuroPace also completed a $65 million common stock offering in early 2025, underscoring active balance-sheet management and the funding needs associated with growth and product development. ([investors.neuropace.com](https://investors.neuropace.com/news/news-details/2026/NeuroPace-Reports-First-Quarter-2026-Financial-Results-and-Raises-2026-Revenue-Guidance/?utm_source=openai)) Overall, NeuroPace is a Nasdaq-listed U.S. small-cap medtech company focused on epilepsy innovation, with a business model built around a flagship device, a clearly defined clinical niche, and recent catalysts tied to RNS growth, potential indication expansion and financial discipline. ([investors.neuropace.com](https://investors.neuropace.com/news/news-details/2026/NeuroPace-Reports-First-Quarter-2026-Financial-Results-and-Raises-2026-Revenue-Guidance/?utm_source=openai))